Search
for
Sort by
Research 30 of 1000+
- Prophylaxis and Management of Skin Toxicities
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous toxicities of new treatments for melanoma
- Cutaneous Toxicities From Transplantation-Related Medications
- Management of Dermatologic Toxicities
- Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Cutaneous toxicities of cancer therapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Incidence and management of cutaneous toxicities associated with cetuximab
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cutaneous adverse effects of targeted therapies
- Dermatological adverse events with taxane chemotherapy
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Prevention of erlotinib-induced folliculitis with doxycycline
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy